The global liquid biopsy market size stood at US$ 3.7 Bn in 2022 and is expected to increase at a CAGR of 8.8% from 2023 to 2031, reaching US$ 7.7 Bn by the end of 2031. The liquid biopsy market is rapidly transforming the global diagnostics and oncology landscape by offering minimally invasive solutions for cancer detection, monitoring, and treatment planning. Unlike traditional tissue biopsies, liquid biopsy techniques analyze biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes from blood samples, enabling faster and less invasive diagnosis. As precision medicine continues to gain traction worldwide, liquid biopsy technologies are emerging as a critical tool in personalized healthcare and advanced disease management.

Access key findings and insights from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=22994

Market Overview

The liquid biopsy market has witnessed remarkable progress over the past decade due to rising cancer prevalence, increasing demand for non-invasive diagnostic methods, and advancements in genomic technologies. Healthcare providers and researchers are increasingly adopting liquid biopsy solutions because they offer real-time insights into tumor progression and treatment response without the need for surgical procedures. The technology is particularly valuable in oncology, where early detection and continuous monitoring can significantly improve patient outcomes. In addition to cancer diagnostics, liquid biopsy applications are expanding into prenatal testing, organ transplant monitoring, and infectious disease detection, highlighting the broad potential of this innovative technology. Continuous improvements in sequencing technologies and biomarker analysis are further enhancing the accuracy and reliability of liquid biopsy platforms.

Market Size and Growth

Valued at US$ 3.7 Bn in 2022, the global liquid biopsy market is projected to reach US$ 7.7 Bn by 2031, expanding at a CAGR of 8.8% during the forecast period. The market growth is being driven by increasing investments in precision medicine, rising healthcare expenditures, and growing awareness regarding early cancer detection. Governments and healthcare organizations across the globe are emphasizing the development of advanced diagnostic technologies to improve disease management and reduce healthcare burdens. Additionally, pharmaceutical companies are increasingly utilizing liquid biopsy tools in clinical trials and drug development processes, further accelerating market expansion. The growing adoption of next-generation sequencing (NGS) and companion diagnostics is also expected to contribute significantly to long-term market growth.

Market Segmentation

The liquid biopsy market can be segmented based on biomarker type, application, technology, and end-user. By biomarker type, the market includes circulating tumor cells, circulating tumor DNA, extracellular vesicles, and other analytes, with ctDNA holding a significant share due to its high clinical relevance in cancer diagnostics. In terms of application, the market is categorized into cancer screening, treatment monitoring, recurrence monitoring, and non-oncology applications. Among these, cancer screening and treatment monitoring dominate due to rising demand for personalized medicine solutions. Based on technology, the market includes polymerase chain reaction (PCR), next-generation sequencing, and other advanced analytical methods. Hospitals, diagnostic laboratories, and research institutes represent key end-users driving adoption globally.

Regional Analysis

Regionally, North America leads the liquid biopsy market, supported by advanced healthcare infrastructure, strong research activities, and high adoption of innovative diagnostic technologies. The United States remains a major contributor due to substantial investments in cancer research and the presence of leading biotechnology firms. Europe also represents a significant market, driven by increasing awareness regarding early cancer detection and supportive government initiatives. Meanwhile, Asia-Pacific is anticipated to witness the fastest growth during the forecast period owing to expanding healthcare infrastructure, rising cancer incidence, and growing investments in biotechnology sectors across countries such as China, India, and Japan. Emerging economies in Latin America and the Middle East & Africa are also gradually adopting advanced diagnostic solutions.

Competitive Landscape

Leading companies are following the latest liquid biopsy market trends and focusing on research and development initiatives, strategic collaborations, and the commercialization of advanced liquid biopsy technologies. Key players are engaged in organic as well as inorganic modes of expansion to strengthen their global presence. Prominent entities operating in the global market include Biocept, Inc., MDxHealth, Myriad Genetics, Inc., Bio-Rad Laboratories, QIAGEN, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Genomic Health, Inc., and Illumina, Inc. These companies are continuously investing in innovative product development, partnerships, mergers, and acquisitions to enhance their competitive positioning and broaden their technological capabilities in precision diagnostics.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453